Fluidigm Corporation (FLDM) was Reiterated by Leerink Partners to “Outperform” while Lowering the Price Target of the company shares to $ 15 from a previous price target of $20 . Leerink Partners advised their investors in a research report released on Apr 12, 2016.
Many Wall Street Analysts have commented on Fluidigm Corporation. Shares were Reiterated by Leerink Partners on Apr 12, 2016 to “Outperform” and Lowered the Price Target to $ 15 from a previous price target of $20 .
On the company’s financial health, Fluidigm Corporation reported $-0.45 EPS for the quarter, missing the analyst consensus estimate by $ -0.02 based on the information available during the earnings call on Feb 4, 2016. Analyst had a consensus of $-0.43. The company had revenue of $30.70 million for the quarter, compared to analysts expectations of $30.35 million. The company’s revenue was down -8.4 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.39 EPS.
Fluidigm Corporation (FLDM) witnessed a volatile trading activity on Monday , and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $8.83 and reached the intraday high at $9.08. The bulls started the profit booking and pushed the shares to intraday low of $8.735. The trading session was marked by a volume range of 2,31,781 shares exchanging hands. The 52-week high of the shares is $45.64 and the 52-week low is $4.84. The market cap of the company stands at $254 M and there are 2,88,44,206 shares in public circulation.
In a different news, on Nov 6, 2015, Gajus Vincent Worthington (PRESIDENT & CEO) sold 6,000 shares at $11.50 per share price. According to the SEC, on Jun 18, 2015, Vikram Jog (CHIEF FINANCIAL OFFICER) sold 3,550 shares at $25.00 per share price. On Jun 17, 2015, William Maxwell Smith (EVP, LEGAL AFFAIRS & GC) sold 3,000 shares at $24.20 per share price, according to the Form-4 filing with the securities and exchange commission.
Fluidigm Corporation creates manufactures and market technologies and life science tools focused on the exploration and analysis of single cells as well as the industrial application of genomics based upon the Companys core microfluidics and mass cytometry technologies. The Company also offers instruments and consumables to academic institutions clinical laboratories pharmaceutical biotechnology and agricultural biotechnology (Ag-Bio) companies. The Company sells technologies and life-science tools including analytical and preparatory systems for genomic and proteomic analysis and consumables including Integrated Fluidic Circuits (IFCs) assays and reagents. The Companys products include C1 Single-Cell Auto Prep System; Access Array System; Biomark HD System; EP1 System; CyTOF 2 System; IFCs include C1 IFCs; Access Array IFC; Dynamic Array IFCs; Digital Array IFCs; Flex Six IFC; Access Array Target-Specific Primers and Maxpar Reagents among others.